Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Inclusion Criteria: * Body Mass Index (BMI) \> 25 kg/m² * Visceral Fat Area (VFA) \> 100 cm² * Triglycerides (TG) \> 150 mg/dL and \< 700 mg/dL, and/or HDL-cholesterol \< 40 mg/dL(Dyslipidemia) * At least 1 criteria of the following 2 comorbidities: * Impaired Glucose Tolerance or Type 2 diabetes * Hypertension Exclusion Criteria: * Patient with a secondary obesity. * Patients who have received the diet therapy for less than 8 weeks before start of the observation period. * Patients whose body weight changed by more than the variation of ± 2kg for screening period. * Low compliance to drug intake (\< 80%) and dietary instruction during the observation period. * Patients with type 1 diabetes. * Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial combined hyperlipidemia and familial type III hyperlipidemia). * Patients with a LDL-cholesterol \> 190 mg/dL at any of Weeks -8 or -4. * Patients with a secondary hypertension.